NEW DELHI: Bharat Biotech’s intranasal COVID-19 vaccine approved for emergency use authorization by the centre can now be procured across hospitals private or government.
iNNOVACC is now available on Co-WIN, priced at Rs800 for private hospitals and Rs325 for a government hospitals. The ministry’s approval for the intranasal vaccine as a booster comes amid a spurt in Covid cases in China and some other countries. “The vaccine branded as iNCOVACC is likely to be introduced on the Co-WIN platform Friday evening onwards. For now, it will be available in private hospitals,” an official source said.
The nasal vaccine — BBV154 — had received approval of the Drugs Controller General of India (DCGI) in November for restricted use in an emergency situation for those above 18 years as a heterologous booster dose
This is India’s first nasal vaccine that will be rolled out in the fourth week of January as a booster dose for those above 18 years of age. This needle free vaccine is approved for administration as a booster dose for those for those previously jabbed with COVAXIN or COVISHIELD.